Rocket Pharmaceuticals (NASDAQ:RCKT) Earns “Buy” Rating from Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $62.00 target price on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on RCKT. JPMorgan Chase & Co. increased their […]
More Stories
TrinityPoint Wealth LLC Makes New Investment in Everest Group, Ltd. (NYSE:EG)
TrinityPoint Wealth LLC purchased a new position in Everest Group, Ltd. (NYSE:EG – Free Report) in the third quarter, Holdings...
Septerna (NASDAQ:SEPN) Now Covered by JPMorgan Chase & Co.
Investment analysts at JPMorgan Chase & Co. began coverage on shares of Septerna (NASDAQ:SEPN – Get Free Report) in a...
Insider Selling: Rollins, Inc. (NYSE:ROL) Major Shareholder Sells 14,750 Shares of Stock
Rollins, Inc. (NYSE:ROL – Get Free Report) major shareholder Timothy Curtis Rollins sold 14,750 shares of the stock in a...
The Trade Desk, Inc. (NASDAQ:TTD) Stock Position Lowered by Parnassus Investments LLC
Parnassus Investments LLC trimmed its position in shares of The Trade Desk, Inc. (NASDAQ:TTD – Free Report) by 1.5% during...
FWG Holdings LLC Has $551,000 Holdings in Tyler Technologies, Inc. (NYSE:TYL)
FWG Holdings LLC increased its position in shares of Tyler Technologies, Inc. (NYSE:TYL – Free Report) by 3.1% in the...
Parnassus Investments LLC Sells 29,095 Shares of Otis Worldwide Co. (NYSE:OTIS)
Parnassus Investments LLC lowered its stake in Otis Worldwide Co. (NYSE:OTIS – Free Report) by 3.4% during the third quarter,...